Welcome, visitor! [ Register | Login

Post an IOI
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Join Clearing and Settlement Now!

Value of Assets Posted

Est. over 8+ Billion in assets posted

IBKR

Featured Service Providers

  • Eurex Clearing
  • KDPW_CCP
  • CSOB
  • ACSA
  • Escrow.com
  • Orbis
  • FirstBank Nigeria
  • Confidebat
  • Screen Shot 2012-09-06 at 12.30.19 PM

Activity

  • Public Info posted an update 1 month, 3 weeks ago

    InvestorNewsBreak

    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

    Home / InvestorWire NewsRoom / InvestorNewsBreaks /

    October 11, 2021

    Sectors:

    Biotechnology

    Psychedelics

    InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

    Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain barrier and effectively respond to pain and addiction concerns. Tryp’s efforts come as the Drug Enforcement Administration (“DEA”) recently “proposed a huge increase in the production of marijuana and psilocybin for research purposes with the hope of accelerating new federally approved therapeutic medication. The White House then issued a set of recommendations to Congress asking lawmakers to consider addressing addiction worries and proposals for new clinical research involving marijuana and psychedelics by changing the way select hallucinogen substances are regulated.”

    To view the full article, visit https://ibn.fm/cL68X

    About Tryp Therapeutics Inc.

    Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit http://www.TrypTherapeutics.com.

    NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

    About InvestorWire

    InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

    With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

    Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

    For more information, please visit https://www.InvestorWire.com

    Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

    InvestorWire (IW)
    8033 Sunset Blvd Suite 1037-IW
    Los Angeles, CA 90046
    310.299.1717 Office
    http://www.InvestorWire.com
    Editor@InvestorWire.com

    InvestorWire is part of the InvestorBrandNetwork.

    Video courtesy of IPO-VID In Patrick’s Opinion

Stock Investor Daily

Premium Wordpress Themes